Semax Research FAQ: Common Questions Answered in a Research Context

Q: What is Semax?

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a research analogue of the N-terminal fragment of adrenocorticotropic hormone (ACTH) — specifically the ACTH(4-7) region — with a Pro-Gly-Pro tripeptide appended at its C-terminus to improve stability in laboratory conditions [1]. Because its N-terminal core overlaps structurally with alpha-melanocyte-stimulating hormone (α-MSH), research literature classifies Semax as a synthetic melanocortin derivative [1]. It emerged primarily from Russian neuroscience and pharmacology research programs.

Q: What is the difference between Semax and ACTH?

ACTH (adrenocorticotropic hormone) is a 39-amino-acid peptide produced endogenously by the pituitary gland; its primary characterized role in the literature involves stimulating cortisol release from the adrenal cortex. Semax is a much shorter, synthetic fragment: seven amino acids corresponding to ACTH residues 4 through 7 with a Pro-Gly-Pro stabilizer. Published research has examined Semax for interactions with melanocortin-pathway receptors and neurotrophin gene expression [1, 2], which differ substantially from the adrenal-stimulating function associated with full-length ACTH. The two are related by sequence but are studied in quite different research contexts.

Q: What signaling pathways has published research examined for Semax?

The published pre-clinical literature has primarily examined Semax in the context of:

• Neurotrophin signaling — specifically BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), and TrkB (the primary BDNF receptor). Multiple rodent studies have reported changes in the mRNA and protein levels of these factors following Semax administration in animal models [3, 4].
• Melanocortin receptor interactions — given Semax's structural derivation from the ACTH/α-MSH family. The five known melanocortin receptor subtypes (MC1R–MC5R) are the framing system for this research [2].
• Monoaminergic system markers — a rodent study examined striatal serotonergic and dopaminergic parameters following Semax administration [5].
• Transcriptomic changes in ischemia models — genome-wide RNA-Seq studies in rodent middle cerebral artery occlusion models have characterized Semax's effects on gene-expression programs involving neurotrophin, immune, and neurotransmitter pathways [6, 7].

All of these represent laboratory findings in animal or cell-based models. They are not established human mechanisms.

Q: How does Semax differ from Selank?

Semax and Selank are both synthetic heptapeptides with Pro-Gly-Pro C-terminal extensions, and both emerged from Russian research programs, but they have different structural origins and different primary studied receptor systems. Semax is derived from ACTH(4-7); Selank is derived from tuftsin, an endogenous tetrapeptide associated with immune function. The Semax literature is oriented toward melanocortin-pathway and neurotrophin interactions; the Selank literature has focused more on GABAergic system interactions — with one study characterizing Selank as a concentration-dependent allosteric modulator of GABA-A receptors [8] — and on enkephalin-degrading enzyme inhibition. Both compounds have been studied together using resting-state fMRI in healthy research participants, with investigators examining functional connectivity differences between the two conditions [9]. For a full comparison, see the dedicated [Semax vs. Selank spoke](/blog/semax-vs-selank).

Q: What does the Semax literature say about BDNF?

BDNF (brain-derived neurotrophic factor) is a protein involved in neurotrophin signaling. A 2004 in-vivo rodent study reported that Semax stimulated BDNF expression across multiple rat brain regions, with measured changes at both mRNA and protein levels, and also affected TrkB (the primary BDNF receptor) expression [3]. A subsequent study compared the temporal dynamics of BDNF and NGF gene expression across hippocampus, frontal cortex, and retina following Semax administration, finding that the direction and magnitude of expression changes were region- and time-dependent [4]. Studies in rodent ischemia models have reported that Semax-treated animals showed differential neurotrophin gene expression compared to controls, as part of broader transcriptome-level analyses [6, 7]. These are animal and cell-based observations; they do not establish what Semax does to BDNF in humans.

Q: Has Semax been studied in any human research?

The human research on Semax is limited. Most of the published literature involves rodent models and in-vitro (cell-culture) assays. The published studies closest to human investigation are functional neuroimaging studies. One study examined Semax's effects on the default mode network (a resting-state brain network) using fMRI [10]. A separate study examined both Semax and Selank using whole-brain resting-state fMRI in 52 healthy adult research participants, comparing functional connectivity patterns before and after administration [9]. These are mechanistic neuroimaging studies in a healthy-volunteer context — not clinical trials assessing therapeutic outcomes. Semax is not an approved pharmaceutical product in most jurisdictions, and its safety and efficacy in humans has not been established through controlled clinical trials.

Q: Is Semax the same as "nootropic" compounds sold in some markets?

The popular "nootropic" label is applied to Semax based on the studied signaling systems in the pre-clinical literature (melanocortin/neurotrophin interactions, monoaminergic system effects in rodents). This label is not a validated clinical classification, and "nootropic" is not an approved category of drug effect. Responsible research framing describes Semax in terms of what laboratory studies have observed — receptor pathway associations, transcriptional changes in animal models, neuroimaging signal differences in research participants — not in terms of cognitive or neurological benefits in people. At Obsessed Living, Semax is supplied for research use only, not for human consumption.

Q: What is the source and status of the Semax research literature?

The Semax research base is substantially concentrated in Russian academic and pharmaceutical research institutions, which reflects the compound's development history. This is relevant context when evaluating the literature — the body of work, while meaningful at a pre-clinical level, has not been replicated through the kinds of independent, multi-center clinical programs that characterize pharmaceutical development in most Western regulatory systems. Recent research published in international journals (including PMC-indexed open-access studies) has begun to extend this literature, but the pre-clinical model remains the dominant frame.

For more on the specific signaling pathways, see [Semax, BDNF & Melanocortin Signaling](/blog/semax-bdnf-melanocortin). For a comparison with Selank, see [Semax vs. Selank: What the Research Compares](/blog/semax-vs-selank). For the full overview, see the [Semax research pillar](/research/semax).